



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Provigil (modafinil)

Page: 1 of 4

Effective Date: 6/26/2024

Last Review Date: 6/5/2024

Applies  Illinois

Florida

Michigan

to:  New Jersey

Maryland

Florida Kids

### Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Provigil (modafinil) under the patient's prescription drug benefit.

### Description:

Provigil (modafinil) is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea, or shift work disorder.

### Limitations of Use

In obstructive sleep apnea (OSA), Provigil (modafinil) is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating and during treatment with Provigil (modafinil) for excessive sleepiness.

### Compendial Uses/Limited Treatment Option

Fatigue related to multiple sclerosis<sup>8,9</sup>

Idiopathic hypersomnia<sup>6</sup>

### Applicable Drug List:

Modafinil

### Policy/Guideline:

**The requested drug will be covered with prior authorization when the following criteria are met:**

- The patient has a diagnosis of narcolepsy

**AND**

- The request is for continuation of therapy

**AND**

- The patient had a positive response to treatment

**OR**

- The requested drug is being prescribed by, or in consultation with, a sleep specialist

**AND**

- The diagnosis is confirmed by sleep lab evaluation

**OR**

- The patient has a diagnosis of shift work disorder (SWD)

**AND**

- The request is for continuation of therapy

**AND**



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Provigil (modafinil)

Page: 2 of 4

Effective Date: 6/26/2024

Last Review Date: 6/5/2024

Applies  Illinois

Florida

Michigan

to:  New Jersey

Maryland

Florida Kids

- The patient had a positive response to treatment

**AND**

- The patient is still a shift-worker

**OR**

- The requested drug is being prescribed by, or in consultation with, a sleep specialist

**AND**

- A sleep log and actigraphy monitoring have been completed for at least 14 days and show a disrupted sleep and wake pattern

**AND**

- Symptoms have been present for 3 or more months

**OR**

- The patient has a diagnosis of obstructive sleep apnea (OSA)

**AND**

- The request is for continuation of therapy

**AND**

- The patient had a positive response to treatment

**AND**

- The patient is compliant with using continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP)

**OR**

- The requested drug is being prescribed by, or in consultation with, a sleep specialist

**AND**

- The diagnosis has been confirmed by polysomnography

**AND**

- The patient has been receiving treatment for the underlying airway obstruction (continuous positive airway pressure [CPAP] or bilevel positive airway pressure [BIPAP]) for at least one month

**AND**

- Treatment with continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BIPAP) will continue

**OR**

- The requested drug is being prescribed for idiopathic hypersomnia

**AND**

- The request is for continuation of therapy

**AND**

- The patient had a positive response to treatment

**OR**

- The requested drug is being prescribed by, or in consultation with, a sleep specialist

**AND**



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name:	Provigil (modafinil)	Page:	3 of 4
Effective Date:	6/26/2024	Last Review Date:	6/5/2024
Applies to:	<input checked="" type="checkbox"/> Illinois <input type="checkbox"/> New Jersey	<input type="checkbox"/> Florida <input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan <input type="checkbox"/> Florida Kids

- The patient has experienced the presence of daytime lapses into sleep or daily irrepressible periods of need to sleep for at least 3 months  
**AND**
- Insufficient sleep syndrome has been ruled out such as by lack of improvement of sleepiness after an adequate trial of increased nocturnal time in bed, preferably confirmed by at least a week of sleep log with wrist actigraphy  
**AND**
- A multiple sleep latency test (MSLT) documented fewer than two sleep onset rapid eye movement periods (SOREMPs) or no SOREMPs if the REM latency on the preceding polysomnogram was less than or equal to 15 minutes  
**AND**
- Sleep lab evaluation showed at least ONE of the following: A) mean sleep latency on multiple sleep latency test (MLST) of less than or equal to 8 minutes, B) total 24-hour sleep time of greater than or equal to 660 minutes on 24-hour polysomnographic monitoring after correcting any chronic sleep deprivation or by wrist actigraphy in association with a sleep log and averaged over at least 7 days of unrestricted sleep  
**AND**
- The patient does not have cataplexy  
**AND**
- Hypersomnolence or multiple sleep latency test (MSLT) results are not better explained by ANY of the following: A) another sleep disorder, B) other medical or psychiatric disorder, C) use of drugs or medications

**OR**

- The requested drug is being prescribed for multiple sclerosis-related fatigue

**Approval Duration and Quantity Restrictions:**

**Approval:** 12 months

**Quantity Level Limit:** 60 tablets per 30 days

**References:**

1. Provigil [package insert]. Parsippany, NJ: Teva Pharmaceuticals; December 2022.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed December 4, 2023.
3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 12/04/2023).
4. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. *J Clin Sleep Med*. 2017;13(3):479-504.
5. Epstein LJ, Kristo D, Strollo PJ, et al. Clinical Guidelines for the Evaluation, Management and Long-term Care of Obstructive Sleep Apnea in Adults. *J Clin Sleep Med*. 2009;5(3):263-276.
6. American Academy of Sleep Medicine. International Classification of Sleep Disorders, 3<sup>rd</sup> edition, text revision. American Academy of Sleep Medicine, 2023.



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Provigil (modafinil) Page: 4 of 4

Effective Date: 6/26/2024 Last Review Date: 6/5/2024

Applies to:  Illinois  Florida  Michigan  
 New Jersey  Maryland  Florida Kids

7. Sateia MJ. International Classification of Sleep Disorders- Third Edition: Highlights and Modifications. *CHEST*. 2014;146(5):1387-1394.
8. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. *J Clin Sleep Med*. 2021;17(9):1881-1893.
9. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. *J Clin Sleep Med*. 2021;17(9):1895-1945.
10. National Multiple Sclerosis Society. Fatigue. Available at: <https://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms/Fatigue>. Accessed December 4, 2023.
11. Shangyan H, Kuiqing L, Yumin X, et al. Meta-analysis of the efficiency of modafinil versus placebo in the treatment of multiple sclerosis fatigue. *Mult Scler Relat Disord*. 2018;19:85-89.
12. Trotti LM, Becker LA, Friederich Murray C, et al. Medications for daytime sleepiness in individuals with idiopathic hypersomnia. *Cochrane Database Syst Rev*. 2021;5(5):CD012714.